top of page

Vivek K. Vishnudas

VP, Drug Discovery Non-Clinical Dev, CTO and R&D Site Head at BPGbio

Dr. Vivek Vishnudas serves as the Chief Technology Officer and R&D Site Head for
BPGbio Inc. He oversees the development of experimental therapeutics from
conception and drug discovery to IND filing and First-in-Human studies. Dr.
Vishnudas leads an interdisciplinary discovery and early development team that is
conducting pioneering research in Ubiquitin Conjugating Enzyme (E2) biology and
drug discovery. He manages the external R&D collaborations with industrial and
academic partners and aims to scale up BPGbio’s R&D therapeutics portfolio. His
breadth of operations covers scientific leadership, strategic R&D initiatives, and
intellectual property strategies. He is an inventor of the early stage E2 based
Targeted Protein Degradation platform and drug candidates entering IND and
First in Human trials. Prior to serving at BPGbio, Dr Vishnudas was an integral
team member at Berg LLC that developed and operationalized the AI based
Interrogative Biology® platform for target deconvolution and patient
stratification.
Dr. Vishnudas was a research fellow in the Senator Paul D. Wellstone Center for
Excellence in Muscular Dystrophy/BBRI, where he completed his postdoctoral
training. Through his graduate school (University of Vermont) and postdoctoral
fellowship, Vivek received extensive training in the field of muscle physiology and
skeletal muscle diseases. Dr. Vishnudas received a master’s degree in
Biochemistry from the National Dairy Research Institute (NDRI, ICAR India) and a
Ph.D. in Biology from the University of Vermont USA.

Share
  • LinkedIn
  • Youtube
  • X
  • Instagram
How we drive innovation
STORIES
MEETINGS
MEMBERS
Speakers
bottom of page